ClinicalTrials.gg
CompletedNCT00642122Updated Jan 24, 2011

Adults With Moderate to Severe Asthma

A Phase 3 interventional study of Budesonide and Budesonide in Asthma, sponsored by AstraZeneca. Completed. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2011-01-24.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Planned enrollment
16th of 108
900 · median 124
Started
2003
with 5 others
Phase 3
51 of 110
3 open now
Registered
39th of 110
by date
Lead sponsor
41 of 110
AstraZeneca

Among the 110 studies testing budesonide in Asthma, this one is the 16th largest by planned enrollment of the 108 interventional ones that give a count, is one of 6 that started in 2003, is one of 51 in phase 3, and was the 39th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

A study to compare the safety and effectiveness of 5 different ways of taking Pulmicort when given to asthma patients aged 12 years and above.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Pulmicort
  • budesonide
  • respules
  • turbuhaler
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 12 or over who have asthma
  • Ability to properly use an electronic diary
  • Able and willing to nebulize for up to 20 minutes every morning and evening

Exclusion criteria

Exclusion Criteria:

  • Hospitalised at least one once or required emergency treatment due to asthma in the previous 6 months
  • Planned hospitalisation during the study
  • pregnant women or women planning to become pregnant
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single
Enrollment
900 participants (estimated)

Study arms

  • Experimental
    1

    Pulmicort RESPULES

    Drug: Budesonide

  • Experimental
    2

    Pulmicort TURBUHALER

    Drug: Budesonide

Interventions

  • 0.5mg once daily

    Also known as: Pulmicort RESPULES

  • 1mg once daily

    Also known as: Pulmicort RESPULES

  • 1mg twice daily

    Also known as: Pulmicort RESPULES

  • 2mg once daily

    Also known as: Pulmicort RESPULES

  • 4.00mcg twice daily

    Also known as: Pulmicort TURBUHALER

06

What researchers measure

Primary outcomes

  1. Forced Expiratory Volume in 1 second in patients allocated treatment with Pulmicort REPSULES at 0.5mg and 2.0mg.

    Time frame: Day -14, 1, and every 28 days thereafter

Secondary outcomes

  1. Percentage of symptom free days

    Time frame: Day -14, 1, and every 28 days thereafter

  2. Percentage of symptom free nights

    Time frame: Day -14, 1, and every 28 days thereafter

  3. Percentage of symptom free 24-hours

    Time frame: Day -14, 1, and every 28 days thereafter

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2003, a primary completion of Dec 2004 and a completion of Dec 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2008
First posted
Mar 24, 2008
Start
Apr 2003
Primary completionActual
Dec 2004
CompletionActual
Dec 2004
Last update
Jan 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00642122
Lead sponsor
AstraZeneca
First posted
Mar 24, 2008
Start date
Apr 2003
Primary completion
Dec 2004
Completion
Dec 2004
Last update
Jan 24, 2011

Study contacts

Bertil Andersson
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion